Targeted drug trial offers hope for Tough-to-Treat bone cancer
NCT ID NCT04278781
Summary
This study is testing whether the drug AG-120 is safe and effective for people with advanced or returning chondrosarcoma, a type of bone cancer, that has a specific genetic change called an IDH1 mutation. The main goal is to see if the drug can stop the cancer from growing. The trial is for adults whose cancer has worsened recently and who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University (Specimen Analysis Only)
New York, New York, 10032, United States
-
Johns Hopkins Hospital (Data Collection Only)
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
The Ohio State University (Data Collection Only)
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.